Oral Antibiotic Regimen for MRSA Coverage in Uncomplicated Cellulitis
For uncomplicated cellulitis requiring MRSA coverage, order either clindamycin alone OR the combination of trimethoprim-sulfamethoxazole (TMP-SMX) plus a beta-lactam (cephalexin, amoxicillin, or penicillin). 1
When MRSA Coverage is Actually Needed
The IDSA guidelines are clear that MRSA is an unusual cause of typical cellulitis and coverage is usually unnecessary 1. However, you should include MRSA coverage when cellulitis is associated with:
- Penetrating trauma (especially injection drug use)
- Purulent drainage present
- Evidence of MRSA infection elsewhere in the patient
- Known MRSA nasal colonization
- Systemic inflammatory response syndrome (SIRS) 1
A critical pitfall: In pure cellulitis without abscess, ulcer, or purulent drainage, beta-lactam monotherapy (cephalexin, amoxicillin) is recommended and adding TMP-SMX provides no additional benefit 1.
Specific Oral Antibiotic Options for MRSA Coverage
When MRSA coverage is warranted, your options are:
Single-Agent Therapy
- Clindamycin - covers both MRSA and streptococci 1
Dual-Agent Therapy (when streptococcal coverage also needed)
- TMP-SMX + beta-lactam (cephalexin, amoxicillin, or penicillin) 1
- Doxycycline + beta-lactam (cephalexin, amoxicillin, or penicillin) 1
Important caveat: The activity of doxycycline and TMP-SMX against beta-hemolytic streptococci is not well established, which is why they require combination with a beta-lactam when streptococcal coverage is needed 1.
Evidence Supporting These Recommendations
In a high MRSA-prevalence setting, TMP-SMX demonstrated significantly higher treatment success rates than cephalexin alone (91% vs 74%, P<0.001) for outpatient cellulitis 2. The study found that therapy with an antibiotic not active against community-acquired MRSA was independently associated with treatment failure (adjusted OR 4.22,95% CI 2.25-7.92) 2.
Treatment duration: 5 days is sufficient if clinical improvement has occurred by that time, though treatment should be extended if the infection has not improved 1.
Alternative Considerations
While minocycline has been suggested as potentially superior to TMP-SMX or doxycycline for MRSA skin infections 3, it is not included in the IDSA guideline recommendations and should be considered a second-line option when first-line agents fail.